## Highlights of This Issue 3297

### HIGHLIGHTS

#### AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

#### ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?
Adam M. Lee and Robert B. Diasio
See article p. 3378

#### New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

#### Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Prattiles and David B. Solit

#### The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro and Jennifer A. Low

#### The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo

#### BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Biewalski, and Burkhard Brandt

#### Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

#### Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletic, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønning

#### A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

### MOLECULAR PATHWAYS

#### Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Prattiles and David B. Solit

#### The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro and Jennifer A. Low

### HUMAN CANCER BIOLOGY

#### BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Biewalski, and Burkhard Brandt

#### Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy
Darya Alizadeh, Leying Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie
Role of Type-1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans
Mitsugu Fujita, Michael E. Scheurer, Stacy A. Decker, Heather A. McDonald, Gary Kohanbash, Edward R. Kastenhuber, Hisashi Kato, Melissa L. Bondy, John R. Ohlfest, and Hideho Okada

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang, Xiao-Dong Zhu, Hui-Chuan Sun, Yu-Quan Xiong, Peng-Yuan Zhuang, Hua-Xiang Xu, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, and Zhao-You Tang

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies
Nienke A. de Vries, Sophia W. Bruggeman, Daniëlle Hulsman, Hilda I. de Vries, John Zevenhoven, Tessa Buckle, Bob C. Hamans, William P. Leenders, Jos H. Beijnen, Maarten van Lohuizen, Anton J.M. Berns, and Olaf van Tellingen

IMAGING, DIAGNOSIS, PROGNOSIS

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non–Small Cell Lung Cancer
Erin C. Farlow, Kalpa Patel, Sanjib Basu, Bao-Shiang Lee, Anthony W. Kim, John S. Coon, L. Penfield Faber, Philip Bonomi, Michael J. Liptay, and Jeffrey A. Borgia

CANCER THERAPY: CLINICAL

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulères, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Biaías, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marigiaoula Varla-Leftherioti, Michael Papamichail, Anastasios Thanos, Eric von HoFe, and Constantin N. Baxevanis

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into LoxP-conditional p53(or pten);Ink4a/Arf;K-RasV12;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.